NavDx
Blood-based TTMV-HPV DNA laboratory-developed test used in HPV-driven cancer management and post-treatment recurrence surveillance.
- Developer
- Naveris
- Intended use
- Recurrence Detection
- Cancer scope
- Anal cancer, Head and neck cancer
- Specimen
- Plasma
- Molecular modality
- DNA
- Current version
- Current NavDx commercial assay as of 2026-09
- Evidence context
- 3 structured studies · 5 indexed performance results · 5 sources
Why can reported performance numbers differ? MDI keeps each result attached to its study, population, stage or stratum, test version and source rather than treating performance as a fixed property of the test.